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Background: Parkinson’s disease (PD) is the second most common neurodegenerative movement disorder, caused
by preferential dopaminergic neuronal cell death in the substantia nigra, a process also influenced by oxidative
stress. L-3,4-dihydroxyphenylalanine (L-DOPA) represents the main treatment route for motor symptoms associated
with PD however, its exact mode of action remains unclear. A spectrum of conflicting data suggests that L-DOPA
may damage dopaminergic neurons due to oxidative stress whilst other data suggest that L-DOPA itself may induce
low levels of oxidative stress, which in turn stimulates endogenous antioxidant mechanisms and neuroprotection.
Results: In this study we performed a two-dimensional gel electrophoresis (2DE)-based proteomic study to gain
further insight into the mechanism by which L-DOPA can influence the toxic effects of H2O2 in neuronal cells. We
observed that oxidative stress affects metabolic pathways as well as cytoskeletal integrity and that neuronal cells
respond to oxidative conditions by enhancing numerous survival pathways. Our study underlines the complex
nature of L-DOPA in PD and sheds light on the interplay between oxidative stress and L-DOPA.
Conclusions: Oxidative stress changes neuronal metabolic routes and affects cytoskeletal integrity. Further, L-DOPA
appears to reverse some H2O2-mediated effects evident at both the proteome and cellular level.
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Parkinson’s disease (PD) is the second most common neu-
rodegenerative movement disorder, affecting approxi-
mately 1% of individuals older than 60 years [1]. The
occurrence of PD will most likely double within the next
two decades due to an increase in the aging population
[2]. PD is caused by preferential dopaminergic neuronal
cell death in the substantia nigra, resulting in a reduced
level of dopamine in the striatum. By the time of clinical
diagnosis this region of the brain has irreversibly lost 50–
70% of its neurons compared to unaffected individuals [3].
Despite PD being a complex and multifactorial disease,
oxidative stress and mitochondrial dysfunction are
thought to be major causes of neurodegeneration in PD
[4]. In both idiopathic and genetic PD, oxidative stress is
thought to be a common denominator and the substantia* Correspondence: mollers@stjohns.edu
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unless otherwise stated.nigra of PD subjects exhibit increased levels of oxidized
lipids [5], proteins and DNA [6] and decreased levels of
reduced glutathione (GSH) [7].
L-3,4-dihydroxyphenylalanine (L-DOPA) remains the
most common PD medication as it is converted into dopa-
mine in dopaminergic neurons temporarily relieving motor
symptoms. Despite its widespread use there is clear contro-
versy in the field. Pre-clinical in vivo studies have shown
that L-DOPA can damage dopaminergic neurons due to
oxidative stress and perhaps through other mechanisms
[8,9]. Studies have shown that direct intraniagral infusion of
L-DOPA in rats results in reduced dopaminergic neuron
numbers [10] whilst other studies have demonstrated that
L-DOPA increases the levels of nitric oxide in the substan-
tia nigra and striatum [11,12]. In contrast, many in vitro
studies have shown that L-DOPA may be neuroprotective
through decreased lipid peroxidation [13,14]. Furthermore,
studies have indicated that L-DOPA can act as a neuropro-
tective agent reducing toxicity evoked by stronger oxidants
[15]. Indeed, whether L-DOPA is neurotoxic, or has little tod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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unanswered [16].
Despite numerous studies, the molecular interplay be-
tween oxidative stress and L-DOPA remains fragmented.
In this study we have performed a two-dimensional gel
electrophoresis (2DE)-based proteomic study to gain fur-
ther insight into the effects of L-DOPA in response to
H2O2-mediated oxidative stress in SH-SY5Y neuronal
cells. We show that L-DOPA influences proteome changes
in response to oxidative stress leading to a lowering of re-
active oxygen species (ROS) and increased cell survival in-
dicative of a role in neuronal cell protection.Results and discussion
Cell morphology, viability and proteomic profiling of
neuronal cells in response to H2O2 and L-DOPA treatment
In order to provide a global overview regarding the mech-
anism in which L-DOPA may influence toxic effects of
H2O2 in neuronal cells we performed cell viability analysis
and subsequent proteomic analyses using SH-SY5Y cells.
Although primary neurons or dopaminergic neurons
would be ideal for this study in relation to PD we selected
SH-SY5Y cells based on reproducibility and because they
are dopamine beta hydroxylase active. SH-SY5Y cells were
grown under control conditions and were exposed to
2 mM H2O2, 200 μM L-DOPA or a combination of the
two treatments (2 mM H2O2/200 μM L-DOPA) for eight
hours. Cell morphology analysis (Figure 1A) and cell via-
bility assays (Figure 1B) demonstrated that SH-SY5Y cells
exposed to L-DOPA showed no effect on morphology or
cell viability (Figure 1). By contrast, H2O2 exposure de-
creased cell viability, but this effect was reversed in re-
sponse to co-treatment with L-DOPA (Figure 1). ThisFigure 1 Cell morphology and cell viability of SH-SY5Y cells in respon
morphology of SH-SY5Y cells in response to eight hours of 2 mM H2O2, 20
red cell viability assays of SH-SY5Y cells in response to eight hours of 2 mM
Each data point is the average of three replicate samples and presented as
**p < 0.01.suggested that L-DOPA might have a protective effect to-
wards excess oxidative stress.
Based on these findings we then performed a set of
proteomic analyses on SH-SY5Y cells exposed to the same
treatments as described above. The first experiment fo-
cused on the effects of H2O2 on the neuronal proteome
where we compared the proteome profile of SH-SY5Y
cells under control condition (Table 1; Condition A,
Figure 2A) to cells treated with H2O2 (Table 1; Condition
B, Figure 2B). In this experiment we observed significant
up-regulation of ten proteins (spots 1–10) and significant
down-regulation of six proteins (spots 11–16) compared
to control condition (Table 1). In a second experiment we
compared the proteome profile of cells exposed to L-
DOPA (Table 1; Condition C, Figure 3A) to control cells
and found one detectable protein (spot 17) that changes
in response to L-DOPA exposure (Table 2). Finally, in a
third experiment we compared the proteome profile from
cells exposed to both H2O2 and L-DOPA (Figure 3B; Con-
dition D) to control cells (Figure 2A; Condition A) and
observed up-regulation of five proteins (spots 7–10) and
down-regulation of four proteins (spot 14–16 and 18).
Interestingly in this comparison spot 17 was detected in
response to co-treatment with both H2O2 and L-DOPA
but not in the control (Figures 2 and 3). Although L-
DOPA can auto-oxidize we did not include catalase in
these experiments as our findings show that L-DOPA
treatment can reverse the decreased cell viability in re-
sponse to oxidative stress suggesting the presence of the
active form of L-DOPA in our experimental conditions.
Detailed information on the number of spots detected in
each gel is summarized in Table 1.
We studied and classified the differentially expressed
proteins according to their gene ontology (GO, withse to H2O2, L-DOPA and H2O2/L-DOPA treatments. (A) Cell
0 μM L-DOPA and 2 mM H2O2/200 μM L-DOPA treatments. (B) Neutral
H2O2, 200 μM L-DOPA and 2 mM H2O2/200 μM L-DOPA treatments.
means ± SD. Standard deviations are indicated by error bars.
Table 1 Treatment conditions of the SH-SY5Y neuronal cells
Condition Treatment regime Number of spots detected
in three gels
Spots matched
to replicates
Spots matched
to control
Figure
no.
A Control 1252, 1326, 1277 1212 - 2A
B 2 mM H2O2 - 8 hours 1287, 1202, 1219 1184 1033 2B
C 200 μM L-DOPA - 8 hours 1314, 1280, 1334 1257 1191 3A
D Co-treatment with 200 μM L-DOPA and 2 mM H2O2 - 8 hours 1285, 1274, 1239 1215 1082 3B
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knowledge website: http://www.uniprot.org/) and QuickGO
(http://www.ebi.ac.uk/QuickGO/). Several biological pro-
cesses and pathways were affected due to the treatment
conditions. For instance the majority of protein changes in
response to oxidative stress belong to the “cell motion
(GO:0006928)” category, most of which were reversed by
L-DOPA co-treatment. More detailed information regard-
ing the differentially expressed proteins are illustrated in
Figure 4, summarized in Table 2 and discussed below.Oxidative stress changes metabolic routes
Glutathione is one of the main cellular antioxidants which
prevents damage caused by ROS [17]. The reduced form
of glutathione is oxidized during the conversion of re-
active H2O2 into H2O by glutathione peroxidase and the
oxidized form can be reduced back to its original state via
NADPH and glutathione reductase. The main source of
NADPH in cells is through the pentose phosphate path-
way (PPP, also called the phosphogluconate pathway).Figure 2 Comparison of the proteomes of SH-SY5Y cells with or with
proteomes of SH-SY5Y cells grown for 8 hours in the (A) absence or (B) pr
overrepresented in each condition whereas lowercase letters are used for s
numbered and correspond to the proteins listed in Table 2.We observed a dramatic decrease in the expression of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in
all conditions treated with H2O2 (spot 14 with an aver-
age of 0.22 fold change compared to the control)
(Table 2). GAPDH catalyzes the conversion of glyceral-
dehyde 3-phosphate to D-glycerate 1,3-bisphosphate as
part of glycolysis. GAPDH also acts as reversible meta-
bolic switch under oxidative stress conditions where
cells require excessive amounts of the antioxidant cofac-
tor NADPH [18]. Indeed, it has been shown that oxida-
tive stress causes an inactivation of GAPDH which re-
routes the metabolic flux from glycolysis to the PPP
[19]. This phenomenon in turn allows cells to produce
higher levels of NADPH to overcome the oxidative con-
ditions. Combined with our findings showing H2O2-me-
diated down-regulation of GAPDH, GAPDH modulation
may have neuroprotective potential [20].
Unlike GAPDH, lactate dehydrogenase (LDH, spot 7,
4.52 fold change) is up-regulated in response to H2O2
exposure (Table 2). This cytosolic enzyme, involved in
oxidation-reduction, can catalyze the conversion ofout H2O2. Representative 2-DE gels (n = 3 for each treatment) of the
esence of 2 mM H2O2. The uppercase letters are used for those spots
pots underrepresented. The spots differentially represented are
Figure 3 Proteomes of SH-SY5Y cells exposed to L-DOPA with or without H2O2. Representative 2-DE gels (n = 3 for each treatment) of the
proteomes of SHSY5Y cells grown in media containing 200 μM L-DOPA for 8 hours in the (A) absence or (B) presence of 2 mM H2O2. The
uppercase letters are used for those spots overrepresented in each condition whereas lowercase letters are used for spots underrepresented.
The spots differentially represented are numbered and correspond to the proteins listed in Table 2.
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ever, LDH can also perform the reverse reaction in oxi-
dative conditions and generate NADH.
Similar to the cytosolic routes, oxidative stress impacts
the tricarboxylic acid (TCA) cycle as well as beta-
oxidation of fatty acids in mitochondria. We detected
substantial up-regulation of fumarate hydratase (spot 1,
8.27 fold increase) in response to H2O2, a member of the
TCA cycle that catalyzes the reversible hydration/dehydra-
tion of fumarate to malate (Table 2). The TCA cycle gen-
erates NADH, which can either be used in respiration or
be converted to NADPH via nicotinamide nucleotide
transhydrogenase (NNT). Interestingly, the alteration of
mitochondrial nucleoside-diphosphate kinase (spot 6, 2.7
fold increase), that catalyzes the exchange of phosphate
groups between different nucleoside diphosphates, also
supports the involvement of the TCA cycle in the oxida-
tive stress response in neurons (Table 2).
Our analysis also showed up-regulation of 3-Hydroxyacyl
CoA dehydrogenase (spot 2, 4.81 fold change), an oxidore-
ductase enzyme involved in beta-oxidation of fatty acids
catalyzing oxidation of L-3-hydroxyacyl CoA by NAD+
thus generating NADH in response to oxidative stress
(Table 2).
Neurons respond to oxidative conditions by enhancing
cell survival mechanisms
In the oxidative stress conditions tested we observed up-
regulation of proteins involved in cell survival such as
Annexin A1, Peroxiredoxin-6 and PARK7/DJ-1 (Table 2).Annexin A1 (spot 8, 1.88 fold) is known to be a cal-
cium/phospholipid-binding protein that promotes mem-
brane fusion [22]. This membrane-associated protein
can regulate proliferation and apoptosis via the NF-κB
signal transduction pathway [23,24]. Annexin A1 can
also directly improve cell survival by limiting excessive
levels of ROS during oxidative stress in plant cells. It has
been demonstrated that Annexin A1 from Arabidopsis
thaliana (AnnAt1) is a redox sensor and displays perox-
idase activity [25]. Moreover Rhee and co-workers have
shown that, Annexin I serves as a stress protein in HeLa
cells and that Annexins may constitute a new class of
stress proteins [26].
Similarly, Peroxiredoxin-6, involved in redox regula-
tion of the cell, is highly up-regulated (spot 10, 12.7
fold) in response to H2O2 exposure (Table 2). Peroxire-
doxins represent antioxidants with the capacity to medi-
ate signal transduction in mammalian cells [27]. Indeed,
peroxiredoxin-6 can reduce H2O2 and short chain fatty
acid, and phospholipid hydroperoxides [28]. Moreover,
it has been reported that retinal ganglion cells over-
expressing Peroxiredoxin-6 gain resistance against
hypoxia-evoked generation of ROS and ROS-induced
cellular insults by negatively regulating NF-κB-mediated
death signaling [29].
The substantial up-regulation of PARK7/DJ-1 (spot 9,
8.58 fold), involved in protecting cells against oxidative
stress and cell death, is not entirely surprising (Table 2).
PARK7/DJ-1 has numerous reported functions, including
anti-oxidative stress reactions, transcriptional regulation,
Table 2 Detailed information of spots up-regulated or down-regulated in each treatment condition
Spot
ID
Protein
ID
Description Mass PI Score Protein
coverage
AVG fold
change
p-value q-value GO (Biological Process)
1 P07954 Fumarate hydratase,
mitochondrial
54714 8.85 408 27.2 8.27 2.10E-03 4.68E-04 GO:0009056 ~ catabolic process, GO:0042592 ~ homeostatic
process
2 Q16836 Hydroxyacyl-coenzyme A
dehydrogenase
34613 8.76 118 21.5 4.81 3.22E-04 1.38E-03 GO:0055114 ~ oxidation reduction
3 Q9Y281 Cofilin-2 18764 7.66 113 33.1 7.4 2.75E-05 1.75E-03 GO:0030042 ~ actin filament depolymerization
4 P60981 Destrin 18852 8.14 147 26.1 5.08 1.62E-04 1.75E-03 GO:0006928 ~ cell motion, GO:0043243 ~ positive regulation of
protein complex disassembly
5 P23528 Cofilin-1 18776 8.22 192 50.6 4.1 3.15E-03 1.99E-03 GO:0006928 ~ cell motion, GO:0043243 ~ positive regulation of
protein complex disassembly
6 O00746 Nucleoside diphosphate
kinase
17469 7.77 1024 41.4 2.7 3.71E-03 2.34E-03 GO:0009116 ~ nucleoside metabolic process
7 Q9BYZ2 L-lactate dehydrogenase A-
like 6B
36817 7.62 244 29.6 4.52 1.02E-02 4.48E-03 GO:0055114 ~ oxidation reduction, GO:0006096 ~ glycolysis
8 P04083 Annexin A1 38816 6.57 142 6.62 1.88 3.49E-03 4.48E-03 GO:00070301 ~ cellular response to hydrogen peroxide,
GO:0006954 ~ inflammatory response
9 Q99497 Protein DJ-1 20064 6.33 501 21.2 8.58 4.11E-04 4.48E-03 GO:0006979 ~ response to oxidative stress, GO:0042592 ~
homeostatic process
10 P30041 Peroxiredoxin-6 25109 5.74 348 35.7 12.7 5.85E-04 5.26E-03 GO:0009056 ~ catabolic process, GO:0055114 ~ oxidation
reduction
11 P08670 Vimentin 53754 5.06 1536 62.2 0.08 2.21E-03 5.26E-03 GO:0006928 ~ cell motion
12 P67936 Tropomyosin alpha-4 chain 28620 4.65 138 23.8 0.07 2.47E-02 5.26E-03 GO:0006928 ~ cell motion
13 P09493 Tropomyosin alpha-1 chain 32746 4.69 405 33.1 0.12 2.37E-03 6.41E-03 GO:0006979 ~ response to oxidative stress, GO:0006928 ~ cell
motion, GO:0046907 ~ intracellular transport
14 O14556 Glyceraldehyde-3-
phosphate dehydrogenase
35953 8.49 1165 48.6 0.22 9.05E-03 1.04E-02 GO:0055114 ~ oxidation reduction, GO:0006096 ~ glycolysis,
GO:0006928 ~ cell motion
15 Q9UBR2 Cathepsin Z 34658 6.13 308 15.7 0.18 4.90E-03 1.04E-02 GO:0006508 ~ proteolysis
16 Q08752 Peptidyl-prolyl cis-trans
isomerase D
20436 6.77 139 8.88 0.12 9.20E-03 1.08E-02 GO:0043065 ~ positive regulation of
apoptotic process
17 Q9Y4L1 Hypoxia up-regulated
protein 1
1E + 05 5.09 192 27 N/A N/A N/A GO:0042221 ~ response to chemical stimulus,
GO:0006950 ~ response to stress
18 P10809 60 kDa heat shock protein 61105 5.72 289 29.6 4.77 8.26E-04 2.47E-02 GO:0032943 ~ mononuclear cell proliferation
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Figure 4 Close-up view of protein spots differentially represented in response to H2O2, L-DOPA and H2O2/L-DOPA treatments.
Enlargements of gel portions containing the differentially abundant protein spots indicated in the gels shown in Figures 2 and 3. Column charts
show the ratio for each differentially expressed protein. Differentially expressed proteins were studied using Student's t-test. The relative spot
volume (Vol%) for proteins from the control condition was set to “1”.
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http://www.biomedcentral.com/1471-2202/15/93and mitochondrial regulation [30]. Similar to Annexin A1
and Peroxiredoxin-6, PARK7/DJ-1 is also a stress sensor
and its expression is increased upon oxidative stress and
various other stresses [31,32] playing a role in regulating
the expression or stability of the mitochondrial uncoup-
ling proteins SLC25A14 and SLC25A27 in dopaminergic
neurons [33]. PARK7/DJ-1 is also a transcriptional co-
activator that protects against neuronal apoptosis and it
has been shown that its cytoprotective action is through
inhibition of the p53-Bax-caspase pathway [34]. Moreover,
it is known that PARK7/DJ-1 also enhances cell survival
through the binding of Cezanne, a negative regulator of
NF-kappaB [35].
It is also interesting to note that Cathepsin X (also
known as Cathepsin Z, spot 15, ratio 0.18), involved in
cell death, is attenuated (Table 2). This protein is a lyso-
somal cysteine proteinase and a member of the peptidase
C1 family with both carboxy-monopeptidase and carboxy-
dipeptidase activities [36]. It has been reported that α andγ enolases, showing neurotrophic activity, are molecular
targets for Cathepsin X and that cleavage of C-terminal
amino acids of α and γ enolases by Cathepsin X abolishes
their neurotrophic activity affecting neuronal cell survival
and neuritogenesis [37].
Down-regulation of Cyclophilin D (spot 16, ratio 0.12),
the only human mitochondrial isoform of cyclophilins, is
also notable (Table 2). Cyclophilin D is required for the
formation of the mitochondrial permeability transition
pore leading to cell necrosis [38]. In addition, opening of
the mitochondrial permeability transition pore, orches-
trated by Cyclophilin D, underlies oxidative stress-induced
axonal degeneration [39]. Therefore attenuation of this
protein in response to oxidative stress seems to play a
pivotal role in cell survival.
Cytoskeletal modifications by oxidative stress
Treatment with H2O2 resulted in modification of cell
morphology in the absence of L-DOPA (Figure 1A). Indeed,
Figure 5 Quantitative ROS measurements in response to H2O2,
L-DOPA and H2O2/L-DOPA treatments. Quantification of ROS
production in SH-SY5Y cells in response to eight hours of 2 mM
H2O2, 200 μM L-DOPA and 2 mM H2O2/200 μM L-DOPA treatments
as determined by DCF fluorescence intensity. Each data point is the
average of 12 replicate samples and presented as means ± SD.
Standard deviations are indicated by error bars. ***p < 0.001.
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oxidative stress, indicates a rearrangement of the cytoskel-
eton. We observed up-regulation of all three members of
the ADF/cofilin family including Cofilin-1 (spot 5, 4.1 fold),
Cofilin-2 (spot 3, 7.4 fold) and Destrin, also known as ADF
or actin depolymerizing factor (spot 4, 5.08 fold) (Table 2).
Cofilins control actin polymerization/depolymerization in a
pH-sensitive manner where they bind to actin filaments
(F actin) and regulate actin cytoskeleton dynamics playing a
critical role in the regulation of cytoskeletal organization
and cell morphology [40].
Conversely, other actin binding proteins, such as Tropo-
myosin alpha-4 chain (spot 12, ratio 0.07) and Tropomy-
osin alpha-1 chain (spot 13, ratio 0.12) are down-regulated
(Table 2). These proteins bind to actin filaments in muscle
and non-muscle cells and play a central role in muscle con-
traction and in stabilizing cytoskeleton actin filaments in
non-muscle cells [41].
The down-regulation of Vimentin (spot 11, ratio 0.08)
under oxidative conditions is also remarkable (Table 2).
Vimentin is attached to the endoplasmic reticulum,
mitochondria and nucleus either laterally or terminally
[42]. This cytoskeletal component plays an important
role in anchoring organelles in the cytosol and is respon-
sible for maintaining cell shape, cytoplasmic integrity,
and stabilization of cytoskeletal interactions [43]. Cells
deficient in Vimentin are therefore extremely delicate
[43] suggesting that the observed change in neuronal cell
morphology in response to H2O2 may be due to the ob-
served attenuation of Vimentin (Table 2).
L-DOPA promotes reversal of oxidative stress responses
An interesting phenomenon that was observed in our treat-
ments is the ability of L-DOPA to reverse the effects of
H2O2 on cellular morphology and cell viability (Figure 1).
This reversal was also observed in terms of ROS where L-
DOPA exposure reduced ROS levels, in the presence of
H2O2, down to levels observed in control cells (Figure 5).
Indeed, all the H2O2-induced protein alterations, affecting
the cytoskeleton, were restored to baseline by supplement-
ing the H2O2-containing media with L-DOPA (spots 3, 4, 5,
11, 12 and 13) (Figures 3B, Table 2). Furthermore, the
induction of mitochondrial enzymes under oxidative
stress condition (fumarate hydratase (spot 1), nucleoside-
diphosphate kinase (spot 6) and 3-Hydroxyacyl CoA de-
hydrogenase (spot 2) was abolished in response to
L-DOPA exposure (Table 2).
Effects of L-DOPA
Only cells exposed to L-DOPA under oxidative stress con-
ditions show significantly elevated expression of a 60-kDa
heat shock protein (also known as HSP-60, spot 18, 4.77
fold overexpressed), a mitochondrial protein with cytopro-
tective functions [44]. This observation suggests that L-DOPA can mediate mitochondrial associated cell survival
mechanisms as has been previously reported when expos-
ing postnatal mesencephalic cultures, grown on glia
monolayers, to L-DOPA in excess of 100 μM [45]. This
heat shock protein contributes to the anti-apoptotic
Hsp60/procaspase-3 complex and enhances cell survival
[46]. It has been observed that mild Hsp60 deficiency pri-
marily affects neuronal and/or glia cells, whereas more se-
vere Hsp60 deficiency affects all tissues [47].
In addition to its effects on the cytoskeleton and mito-
chondria, L-DOPA seems to participate in a cell survival
mechanism triggered by oxygen deprivation through induc-
tion of the hypoxia up-regulated protein 1 (ORP150, spot
17), a chaperone involved in protein folding [48]. We ob-
served detectable levels of this protein only in the presence
of L-DOPA regardless of the oxidative stress conditions
(Table 2) suggesting that L-DOPA may aid hypoxia condi-
tion in cells. It has been shown in rat astrocytes that
ORP150 is induced by hypoxia within 24 hours, augmented
further during early re-oxygenation, and thereafter decreas-
ing to baseline levels by 24 hours in normoxia [49]. Fur-
thermore, the hypoxia-mediated induction of ORP150
appears specific as stress conditions such as heat shock,
H2O2, cobalt chloride, 2-deoxyglucose, or tunicamycin does
not affect ORP150 levels [49]. Interestingly, exposure to
dopamine has similar ORP induction effects as hypoxia in
PC12 cells [50]. In the catecholamine synthesis pathway
dopamine is the first catecholamine synthesized from L-
DOPA where norepinephrine and epinephrine are formed
by further metabolic dopamine modifications (Figure 6).
Figure 6 Biosynthesis of catecholamines. The conversion of
L-DOPA to norepinephrine through dopamine requires molecular
oxygen.
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oxygen, thus the higher level of oxygen consumption due
to L-DOPA exposure may cause cellular hypoxia and there-
fore induction of ORP150 with its concomitant cytoprotec-
tive effects.
Our findings, combined with previous data, suggest
that although L-DOPA appears to influence neuronal
cell survival pathways, this is most probably an indirect
effect through the induction of endogenous antioxidant
mechanisms [15].
Conclusion
There is clear controversy surrounding L-DOPA effects
associated with oxidative stress [16]. Using a 2DE-based
proteomic study we have shown that oxidative stress
changes neuronal metabolic routes and affects cytoskeletal
integrity. Interestingly, L-DOPA reverses some of these
H2O2−mediated effects at the cell morphology and cell
viability level (Figure 1), at the ROS level (Figure 5) and atthe protein level (Table 2). Exposure to L-DOPA may aid
hypoxia condition in cells and therefore induction of
ORP150 with its concomitant cytoprotective effects. How-
ever, L-DOPA exposure may simply evoke endogenous
antioxidant mechanisms [15] and it cannot be ruled out
that L-DOPA has direct ROS scavenging action [16]. Our
study sheds light on the molecular interplay linking oxida-
tive stress and L-DOPA in neuronal cells. Furthermore,
the data presented here highlights the complex nature of
L-DOPA in PD, demonstrating that additional studies are
required that addresses L-DOPA action in the context of
appropriate experimental design and choice of model
mimicking PD.
Methods
Reagents and cell culture
Fetal bovine serum (FBS), phosphate buffered saline
(PBS), Dulbecco’s minimum essential medium plus
F12 (DMEM/F12), penicillin and streptomycin were
purchased from Invitrogen (Gaithersburg, MD). Acryl-
amide/ bis-acrylamide, tris base, glycine, ammonium
persulfate, PVDF membrane, TEMED, DTT, SDS, urea,
thiourea, glycerol, ammonium bicarbonate, DMSO, ECL
reagent, bromoplenol blue were purchased from Fisher
Scientific (Pittsburgh, PA). Trypsin and trypan blue
were obtained from Sigma-Aldrich (St. Louis, MO).
SH-SY5Y cells were cultured in DMEM/F12 contain-
ing 10% FBS, 100 U/ml penicillin and 100 mg/ml
streptomycin at 37°C in an atmosphere containing 5%
CO2. In order to perform treatments the media were
supplemented with 2 mM H2O2 (Sigma-Aldrich, MO),
200 μM L-DOPA (Acros Organics, NJ), or a combin-
ation of H2O2/L-DOPA for eight hours (Table 1).
Cell viability
Cell viability was evaluated by the neutral red uptake
assay. 5×104 SH-SY5Y cells/well were seeded in 96-well
tissue culture plates and incubated overnight. The next
day, the culture medium was removed and the cells were
treated with either 2 mM H2O2, 200 μM L-DOPA and
co-treated with 2 mM H2O2 and 200 μM L-DOPA in
serum-free medium for eight hours. Untreated cells were
used as control. Following incubation, cell morphology
was recorded using an EVOS phase-contrast inverted
microscope. The test-medium was then removed and
cells were washed with PBS. Then 100 μl of a neutral
red solution (40 μg/ml) was added in each well. The
plates were incubated at 37°C for 2 hours. After incuba-
tion, the neutral red solution was removed and cells
were washed with 150 μl PBS per well. Following this
150 μl neutral red destaining solution (50% ethanol, 49%
deionized water, 1% glacial acetic acid) was added to the
cells and the plates were rapidly shaken for at least
10 minutes. The absorbance was measured at 540 nm
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VT). The results were reported as a percentage com-
pared to control cells (considered as 100% viable).
Detection of ROS formation
Intracellular ROS levels were detected by measuring the
oxidation of the cell-permeable dye 2′, 7′-dichlorofluor-
escent diacetate (DCF-DA; Sigma-Aldrich, MO) to fluor-
escent DCF. To quantify intracellular ROS levels, 5×104
SH-SY5Y cells/well were seeded in black 96-well plates.
The next day, the culture medium was removed and the
cells were incubated for 45 minutes with 200 μl of DCF-
DA (final concentration 25 μmol)/well. After incubation
cells were washed with PBS and exposed to 2 mM
H2O2, 200 μM L-DOPA and 2 mM H2O2/200 μM L-
DOPA in serum-free medium for eight hours as de-
scribed above. The medium was then removed and cells
were washed again with PBS. Relative fluorescence was
measured using a GloMax®-Multi Detection System
fluorescence plate reader (Promega, WI) at 485 nm exci-
tation and 528 nm emission wavelengths.
Protein sample preparation and 2-D gel electrophoresis
Triplicate batches of SH-SY5Y cells were seeded at 20–30%
confluence and harvested when cell density reached 90%.
After three washes with PBS, healthy cells were harvested
from the plates and solubilized in 500 μl of lysis buffer: 8 M
urea, 4% (w/v) 3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulfonate (CHAPS), 0.5% (v/v) ampholytes (IPG
buffer, GE Healthcare), 25 mM DTT and 0.002% bromo-
phenol blue) and stored at −80°C. The insoluble fraction
was discarded after centrifugation at 13,200 rpm for 5 min.
The supernatant was collected and the protein concentra-
tion was determined according to the Bradford method,
which showed a high reproducibility for this protein extrac-
tion protocol.
A solution containing 850 μg of soluble proteins in the
sample buffer (same as lysis buffer but containing 2%
CHAPS), was loaded onto 24-cm IPG strips (GE Health-
care), with non-linear (NL) pH 3–11 gradients. Focusing
of proteins (using BioRad IEF instrument), equilibration
of the focused IPG strips and the 12.5% SDS-PAGE for
the second dimension (carried out in an Ettan Dalt Six
apparatus (GE Healthcare)) were performed as previ-
ously described [51]. Briefly, proteins were focused at
20°C according to the following program: 1 h, 0 V and
12 h, 30 V (rehydration); 30-min gradient to 10,000 V;
up to 9 h, 10,000 V until 85 kV-h. Focused IPG strips
were equilibrated twice for 15 min in a buffer containing
50 mM Tris–HCl (pH 8.8), 6 M urea, 30% (v/v) glycerol,
2% (w/v) SDS, 0.002% bromphenol blue, and 1% (w/v)
DTT. For the second equilibration step, DTT was re-
placed by 4.0% (w/v) iodoacetamide. In the second di-
mension 12.5% polyacrylamide SDS-PAGE gels were runin an Ettan Dalt Six apparatus (GE Healthcare) for
45 min at 3 watts/gel and then for 4 h at 18 watts/gel.
Gels were stained with Colloidal Coomassie (CC) follow-
ing the “blue silver” staining method (28), using 0.12%
Coomassie Blue G-250 (Sigma), 10% ammonium sulfate,
10% phosphoric acid, and 20% methanol [52,53].
Analysis of differential protein abundance
Two-dimensional images were captured by scanning
stained gels using an ImageScanner II (GE Healthcare)
previously calibrated by using a grayscale marker (East-
man Kodak Co.), digitalized with Labscan 5.00 (v1.0.8)
software (GE Healthcare), and analyzed with the Image-
MasterTM 2D Platinum V7.0 software (GE Healthcare).
Three gels for each condition, obtained from three inde-
pendent cultures (biological replicates), were analysed to
guarantee representative results. After automated spot
detection, spots were checked manually to eliminate any
possible artefacts, such as streaks or background noise.
The patterns of each sample were overlapped and
matched, using landmark features, to detect differentially
expressed proteins. Variability in the number of protein
spots detected among biological replicates was less than
10%, which may be due to experimental variability. Spot
normalization (internal calibration to make the data in-
dependent from experimental variations between gels)
was made using relative volumes to quantify the gel
spots. Relative spot volume (Vol%) corresponds to the
volume of each spot divided by the total volume of all
the spots in the gel. Analysis of each differentially
expressed protein between conditions was performed
using Student's t-test and p < 0.05 was considered statis-
tically significant [51,54,55]. False discovery rate (FDR)
correction for multiple hypothesis testing was performed
according to Storey’s method (q-value <0.05) [56]. Dif-
ferentially expressed proteins were studied further when
the ratio of the relative mean volume for one specific
spot (in three biological replicates) was higher than 1.5
fold (the relative spot volume (Vol%) for proteins from
the control condition was set to “1”).
Protein identification by mass spectrometry
The protein spots of interest were manually excised
from the gel and washed three times with ammonium
bicarbonate/acetonitrile 1:1 (vol/vol) solution. Polyacryl-
amide fragments were dehydrated in acetonitrile and
dried with a vacuum concentrator. Protein reduction
and alkylation were performed by reswelling polyacryl-
amide fragments in 25 mM ammonium carbonate solu-
tion containing 0.15 mg/ml DTT at 56°C. This solution
was replaced by a 25 mM ammonium bicarbonate solu-
tion containing 10 mg/ml 2-iodoacetamide (Bio-Rad) for
45 min at room temperature and in the dark. Fragments
were dried as described above and tryptic cleavage was
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bonate solution containing 0.1 μg trypsin per gel slice
(Promega, WI, USA) for 20 min on ice. The solution was
then replaced by 25 mM ammonium carbonate solution
and digestion carried out overnight at 37°C. Tryptic pep-
tides were extracted at 37°C for 15 min with a 50% (vol/
vol) acetonitrile and 10% (vol/vol) acetic acid solution. A
second extraction was performed under the same conditions.
A third extraction was performed at room temperature for
15 min with 100% acetonitrile. The pooled solution was
dried under vacuum and resuspended in 10 μl 0.1% (vol/vol)
formic acid solution.
Five microliters of each sample were loaded onto a
75 μm × 12 cm column self-packed with 3 μm ReproSil-
Pur C18-AQ beads (Dr. Maisch), eluted with a gradient of
0–40% acetonitrile in 0.1% formic acid over 18 min at
300 nl/min using an Exigent nanoflow HPLC coupled dir-
ectly to an LTQ-Orbitrap mass spectrometer (Thermo Fisher
Scientific). Mass spectra were acquired in data-dependent
analysis mode with one 60 000 resolution MS survey scan
by the Orbitrap and up to eight concurrent MS/MS scans
in the LTQ for the eight most intense peaks selected from
each survey scan. Automatic gain control was set to 2 000
000 for Orbitrap survey scans and 5 000 for LTQ MS/MS
scans. Survey scans were acquired in profile mode and
MS/MS scans were acquired in centroid mode. Mascot
generic format files were generated from the raw data
using DTASuperCharge (version 1.01) for database
searching. Mascot Generic Files combining MS and MS/
MS spectra were automatically created for protein identifi-
cation, and used to interrogate a nonredundant protein
database using a local license of Mascot v 2.2 from Matrix
Science through the Protein Global Server (GPS) v 3.6
(Applied Biosystems). The search parameters were set as
follows: (i) NCBInr (2011.11.21) sequence database was
used; (ii) taxonomy: All entries (16245521 sequences;
5585386883 residues); (iii) fixed and variable modifications
were considered (Cys as S carbamidomethyl derivative and
Met as oxidized methionine); (iv) one missed cleavage site
was allowed; (v) precursor tolerance was 100 ppm and
MS/MS fragment tolerance was 0.3 Da; (vi) peptide
charge: 1+; and (vii) the algorithm was set to use trypsin
as the enzyme. Additional criteria for confident identifica-
tion were that the protein match should have at least 15%
sequence coverage; for a lower coverage, only those
proteins with a Mascot ions score above 54 and at least
two peptides identified in the tandem MS analysis (with a
significance level of p < 0.05), were considered valid.
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